Giselle Sholler
22 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma (NCT06540963) | Giselle Sholler | 2024-12-06 |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma (NCT05489887) | Giselle Sholler | 2022-09-14 |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma (NCT04696029) | Giselle Sholler | 2021-03-29 |
| Beat Childhood Cancer Specimen Banking and Data Registry (NCT04715178) | Giselle Sholler | 2021-02-02 |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma (NCT04301843) | Giselle Sholler | 2020-09-25 |
Track Giselle Sholler automatically
Every clearance here is in the API, with alerts when new ones post.